Wedbush reaffirmed their buy rating on shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) in a research report sent to investors on Monday. Wedbush currently has a $80.00 price target on the stock. Wedbush also issued estimates for Pacira Pharmaceuticals’ Q4 2017 earnings at ($0.31) EPS, FY2017 earnings at ($1.08) EPS, FY2018 earnings at ($1.32) EPS, FY2019 earnings at ($0.37) EPS and FY2020 earnings at $0.85 EPS.

Several other brokerages have also recently weighed in on PCRX. Mizuho restated a buy rating and set a $54.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, July 26th. Canaccord Genuity set a $56.00 price objective on Pacira Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, July 25th. BidaskClub cut Pacira Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, July 27th. BMO Capital Markets raised their price objective on Pacira Pharmaceuticals from $38.00 to $39.00 and gave the company a market perform rating in a research note on Wednesday, November 8th. Finally, Jefferies Group LLC dropped their price objective on Pacira Pharmaceuticals to $52.00 and set a buy rating on the stock in a research note on Thursday, November 9th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $49.21.

Pacira Pharmaceuticals (NASDAQ:PCRX) opened at $44.50 on Monday. Pacira Pharmaceuticals has a twelve month low of $29.81 and a twelve month high of $58.95. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The company had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $68.99 million. During the same period last year, the business earned $0.20 EPS. Pacira Pharmaceuticals’s quarterly revenue was down 1.6% compared to the same quarter last year. equities research analysts anticipate that Pacira Pharmaceuticals will post -0.87 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Pacira Pharmaceuticals, Inc. (PCRX) Given “Buy” Rating at Wedbush” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/11/24/pacira-pharmaceuticals-inc-pcrx-given-buy-rating-at-wedbush.html.

In other Pacira Pharmaceuticals news, Director Mark A. Kronenfeld bought 1,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was purchased at an average cost of $41.60 per share, with a total value of $41,600.00. Following the transaction, the director now directly owns 6,795 shares in the company, valued at approximately $282,672. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO David M. Stack sold 58,885 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $38.34, for a total value of $2,257,650.90. Following the sale, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at $6,102,347.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,735 shares of company stock valued at $2,692,594. Insiders own 6.60% of the company’s stock.

Several institutional investors have recently made changes to their positions in PCRX. Oppenheimer Asset Management Inc. purchased a new stake in shares of Pacira Pharmaceuticals during the 2nd quarter valued at $114,000. Benjamin F. Edwards & Company Inc. increased its position in shares of Pacira Pharmaceuticals by 12.2% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after purchasing an additional 303 shares during the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Pacira Pharmaceuticals by 121.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after purchasing an additional 1,752 shares during the last quarter. QS Investors LLC purchased a new stake in shares of Pacira Pharmaceuticals during the 2nd quarter valued at $157,000. Finally, Ameritas Investment Partners Inc. increased its position in shares of Pacira Pharmaceuticals by 9.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after purchasing an additional 302 shares during the last quarter. 99.79% of the stock is owned by hedge funds and other institutional investors.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.